Review on the protective effects of PACAP in models of neurodegenerative diseases In Vitro and In Vivo

Current Pharmaceutical Design

Volumn 17, Issue 10, 2011, Pages 962-972

  Reglodi, D ^a   Kiss, P ^a   Lubics, A ^a   Tamas, A ^a  

^a UNIVERSITY OF PÉCS   (Hungary)

Author keywords

Alzheimer's disease; Huntington chorea; PACAP; Parkinson's disease

Indexed keywords

ALPHA SECRETASE; AMYLOID BETA PROTEIN; ANTISENSE OLIGODEOXYNUCLEOTIDE; CASPASE 3; DAVUNETIDE; DOPAMINE; HYPOPHYSIS ADENYLATE CYCLASE ACTIVATING POLYPEPTIDE; HYPOPHYSIS ADENYLATE CYCLASE ACTIVATING POLYPEPTIDE 27; HYPOPHYSIS ADENYLATE CYCLASE ACTIVATING POLYPEPTIDE 4-6; HYPOPHYSIS ADENYLATE CYCLASE ACTIVATING POLYPEPTIDE 6-38; NEUROPEPTIDE; REACTIVE OXYGEN METABOLITE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VASOACTIVE INTESTINAL POLYPEPTIDE RECEPTOR 1;

ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; ANTIINFLAMMATORY ACTIVITY; ANTISENSE THERAPY; BRAIN ISCHEMIA; COMPETITIVE INHIBITION; DIABETIC RETINOPATHY; DOPAMINE METABOLISM; DOPAMINERGIC NERVE CELL; DOPAMINERGIC TRANSMISSION; DRUG HALF LIFE; EXPERIMENTAL MODEL; HUNTINGTON CHOREA; IN VITRO STUDY; IN VIVO STUDY; MEMORY DISORDER; NERVE CELL DEGENERATION; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; PARKINSON DISEASE; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RETINA ISCHEMIA; REVIEW; SIGNAL TRANSDUCTION; SUBSTANTIA NIGRA; VENTRAL TEGMENTUM;

ANIMALS; CELL LINE; DISEASE MODELS, ANIMAL; HUMANS; NEURODEGENERATIVE DISEASES; NEUROPROTECTIVE AGENTS; PITUITARY ADENYLATE CYCLASE-ACTIVATING POLYPEPTIDE;

EID: 79958167912     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/138161211795589355     Document Type: Review

References (181)

1. Miyata A, Arimura A, Dahl RR, et al. Isolation of a novel 38 residue-hypothalamic polypeptide which stimulates adenylate cyclase in pituitary cells. Biochem Biophys Res Commun 1989; 164: 567-74.
2. Vaudry D, Falluel-Morel A, Bourgault S, et al. Pituitary adenylate cyclase-activating polypeptide and its receptors: 20 years after the discovery. Pharmacol Rev. 2009; 61: 283-357.
3. Reglodi D, Borzsei R, Bagoly T, et al. Agonistic behavior of PACAP6-38 on sensory nerve terminals and cytotrophoblast cells. J Mol Neurosci 2008; 36: 270-8.
4. Nicot A, DiCicco-Bloom E. Regulation of neuroblast mitosis is determined by PACAP receptor isoform expression. Proc Natl Acad Sci USA 2001; 98: 4758-63.
5. Somogyvari-Vigh A, Reglodi D. Pituitary adenylate cyclase activating polypeptide: a potential neuroprotective peptide. Curr Pharm Des 2004; 10: 2861-89.
6. Botia B, Jolivel V, Burel D, et al. Neuroprotective effects of PACAP against ethanol-induced toxicity in the developing rat cerebellum. Neurotox Res 2011; 19: 423-34.
7. Arimura A, Somogyvari-Vigh A, Weill C, Fiore RC, Tatsuno I, Bay V, Brenneman DE. PACAP functions as a neurotrophic factor. Ann N Y Acad Sci 1994; 739: 228-43.
8. Brenneman DE. Neuroprotection: a comparative view of vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide. Peptides 2007; 28: 1720-6.
9. Bourgault S, Vaudry D, Dejda A, Doan ND, Vaudry H, Fournier A. Pituitary adenylate cyclase-activating polypeptide: focus on structure-activity relationships of a neuroprotective peptide. Curr Med Chem 2009; 16: 4462-80.
10. Dejda A, Jolivel V, Bourgault S, et al. Inhibitory effect of PACAP on caspase activity in neuronal apoptosis: A better understanding towards therapeutic applications in neurodegenerative diseases. J Mol Neurosci 2008; 36: 26-37.
11. Gonzalez-Rey E, Chorny A, Fernandez-Martin A, Varela N, Delgado M. Vasoactive intestinal peptide family as a therapeutic target for Parkinson's disease. Expert Opin Ther Targets 2005; 9: 923-29.
12. Ohtaki H, Nakamachi T, Dohi K, Shioda S. Role of PACAP in ischemic neural death. J Mol Neurosci 2008; 36: 16-25.
13. Shioda S, Ohtaki H, Nakamachi T, et al. Pleiotropic functions of PACAP in the CNS: neuroprotection and neurodevelopment. Ann NY Acad Sci 2006; 1070: 550-60.
14. Waschek JA. Multiple actions of pituitary adenylyl cyclase activating peptide in nervous system development and regeneration. Dev Neurosci 2002; 24: 14-23.
15. Silveira MS, Costa MR, Bozza M, Linden R. Pituitary adenylyl cyclase-activating polypeptide prevents induced cell death in retinal tissue through activation of cyclic AMP-dependent protein kinase. J Biol Chem 2002; 277: 16075-80.
16. Reglodi D, Fabian Zs, Tamas A, et al. Effects of PACAP on in vitro and in vivo neuronal cell death, platelet aggregation, and production of reactive oxygen radicals. Regul Pept 2004; 123: 51-9.
17. Onoue S, Endo K, Ohshima K, Yamija T, Kashimoto K. The neuropeptide PACAP attenuates β-amyloid (1-42)-induced toxicity in PC12 cells. Peptides 2002; 23: 1471-8.
18. Gui LR, Zhou Y, Zhang BL, Li WB. Pituitary adenylate cyclase activating polypeptide protects neuro-2a cells from beta amyloid protein cytotoxicity by modulating intracellular calcium. Sheng Li Xue Bao 2003; 55: 42-6.
19. Shieh PC, Tsao CW, Li JS, et al. Role of pituitary adenylate cyclase-activating polypeptide (PACAP) in the action of ginsenoside Rh2 against beta-amyloid-induced inhibition of rat brain astrocytes. Neurosci Lett 2008; 434: 1-5.
20. Hartfield PJ, Bilney AJ, Murray AW. Neurotrophic factors prevent ceramide-induced apoptosis downstream of c-Jun N-terminal kinase activation in PC12 cells. J Neurochem 1998; 71: 161-9.
21. Vaudry D, Falluel-Morel A, Basille M, et al. Pituitary adenylate cyclase activating polypeptide prevents C2-ceramide-induced apoptosis of cerebellar granule cells. J Neurosci Res 2003; 72: 303-16.
22. Falluel-Morel A, Aubert N, Vaudry D, et al. Opposite regulation of the mitochondrial apoptotic pathway by C2-ceramide and PACAP through a MAP-kinase-dependent mechanism in cerebellar granule cells. J Neurochem 2004; 91: 1231-43.
23. Aubert N, Vaudry D, Falluel-Morel A, et al. PACAP prevents toxicity induced by cisplatin in rat and primate neurons but not in proliferating ovary cells: involvement of the mitochondrial apoptotic pathway. Neurobiol Dis 2008; 32: 66-80.
24. Bhave SV, Hoffman PL. Phosphatidylinositol 3'-OH kinase and protein kinase A pathways mediate the anti-apoptotic effect of pituitary adenylyl cyclase-activating polypeptide in cultured cerebellar granule neurons: modulation by ethanol. J Neurochem 2004; 88: 359-69.
25. Vaudry D, Rousselle C, Basille M, et al. Pituitary adenylate cyclase activating polypeptide protects rat cerebellar granule neurons against ethanol-induced apoptotic cell death. Proc Natl Acad Sci USA 2002; 99: 6398-403.
26. Allais A, Burel D, Roy V, et al. Balanced effect of PACAP and FasL on granule cell death during cerebellar development: a mor phological, functional, and behavioral characterization. J Neurochem 2010; 113: 329-40.
27. Shoge K, Mishima HK, Saitoh T, et al. Attenuation by PACAP of glutamate-induced neurotoxicity in cultured retinal neurons. Brain Res 1999; 839: 66-73.
28. Morio H, Tatsuno I, Hirai A, Tamura Y, Saito Y. Pituitary adenylate cyclase activating polypeptide protects rat-cultured cortical neurons from glutamate-induced cytotoxicity. Brain Res 1996; 741: 82-8.
29. Shintani N, Suetake S, Hashimoto H, et al. Neuroprotective action of endogenous PACAP in cultured rat cortical neurons. Regul Pept 2005; 126: 123-8.
30. Said SI, Dickman K, Dey RD, et al. Glutamate toxicity in the lung and neuronal cells: prevention or attenuation by VIP and PACAP. Ann NY Acad Sci 1998; 865: 226-37.
31. Tomimatsu N, Arakawa Y. Survival-promoting activity of pituitary adenylate cyclase-activating polypeptide in the presence of phosphodiesterase inhibitors on rat motoneurons in culture: cAMPprotein kinase A-mediated survival. J Neurochem 2008; 107: 628-35.
32. Brenneman DE, Hauser JM, Spong C, Phillips TM. Chemokine release is associated with the protective action of PACAP-38 against HIV envelope protein neurotoxicity. Neuropeptides 2002; 36: 271-80.
33. Skoglosa Y, Lewen A, Takei N, Hillered L, Lindholm D. Regulation of pituitary adenylate cyclase activating polypeptide and its receptor type I after traumatic brain injury: comparison with brainderived neurotrophic factor and the induction of neuronal cell death. Neuroscience 1999; 90: 235-47.
34. Ito Y, Arakawa M, Ishige K, Fukuda H. Comparative study of survival signal withdrawal-and 4-hydroxynonenal-induced cell death in cerebellar granule cells. Neurosci Res 1999; 35: 321-7.
35. Kong LY, Maderdrut JL, Jeohn GH, Hong JS. Reduction of lipopolysaccharide-induced neurotoxicity in mixed cortical neuron/ glia cultures by femtomolar concentrations of pituitary adenylate cyclase activating polypeptide. Neuroscience 1999; 91: 493-500.
36. Li M, David C, Kikuta T, Somogyvari-Vigh A, Arimura A. Signaling cascades involved in neuroprotection by subpicomolar pituitary adenylate cyclase-activating polypeptide 38. J Mol Neurosci 2005; 27: 91-105.
37. Yang S, Yang J, Yang Z, et al. Pituitary adenylate cyclaseactivating polypeptide (PACAP) 38 and PACAP4-6 are neuroprotective through inhibition of NADPH oxidase: potent regulators of microglia-mediated oxidative stress. J Pharmacol Exp Ther 2006; 319: 595-603.
38. Wang G, Qi C, Fan GH, Zhou HY, Chen SD. PACAP protects neuronal differentiated PC12 cells against the neurotoxicity induced by a mitochondrial complex I inhibitor, rotenone. FEBS Lett 2005; 579: 4005-11.
39. Chung YC, Seo H, Sonntag KC, Brooks A, Lin L, Isacson O. Cell type-specific gene expression of midbrain dopaminergic neurons reveals molecules involved in their vulnerability and protection. Hum Mol Genet 2005; 14: 1709-25.
40. Deguil J, Jailloux D, Page G, et al. Neuroprotective effects of pituitary adenylate cyclase-activating polypeptide (PACAP) in MPP+-induced alteration of translational control in Neuro-2a neuroblastoma cells. J Neurosci Res 2007; 85: 2017-25.
41. Onoue S, Endo K, Yajima T, Kashimoto K. Pituitary adenylate cyclase activating polypeptide and vasoactive intestinal peptide attenuate glutamate-induced nNOS activation and cytotoxicity. Regul Pept 2002; 107: 43-7.
42. Takei N, Skoglosa Y, Lindholm D. Neurotrophic and neuroprotective effects of pituitary adenylate cyclase activating polypeptide (PACAP) on mesencephalic dopaminergic neurons. J Neurosci Res 1998; 54: 698-706.
43. Tanaka J, Koshimura K, Murakami Y, Sohmiya M, Yanaihara N, Kato Y. Neuronal protection from apoptosis by pituitary adenylate cyclase activating polypeptide. Regul Pept 1997; 72: 1-8.
44. Chang JY, Korolev VV, Wang JZ. Cyclic AMP and pituitary adenylate cyclase activating polypeptide (PACAP) prevent programmed cell death of cultured rat cerebellar granule cells. Neurosci Lett 1996; 206: 181-4.
45. Chang JY, Korolev VV. Cyclic AMP and sympathetic neuronal programmed cell death. Neurochem Int 1997; 31: 161-7.
46. Przywara DA, Kulkarni JS, Wakade TD, Leontiev DV, Wakade AR. Pituitary adenylate cyclase activating polypeptide and nerve growth factor use the proteosome to rescue nerve growth factordeprived sympathetic neurons cultured from chick embryos. J Neurochem 1998; 71: 1889-97.
47. Lioudyno M, Skoglosa Y, Takei N, Lindholm D. Pituitary adenylate cyclase activating polypeptide (PACAP) protects dorsal root ganglion neurons from death and induces calcitonin gene-related peptide (CGRP) immunoreactivity in vitro. J Neurosci Res 1998; 51: 243-56.
48. Vaudry D, Pamantung TF, Basille M, et al. PACAP protects cerebellar granule neurons against oxidative stress-induced apoptosis. Eur J Neurosci 2002; 15: 1451-560.
49. Mester L, Kovacs K, Racz B, et al. Pitutary adenylate cyclase activating polypeptide is protective against oxidative stress in human retinal pigment epithelial cells. J Mol Neurosci 2011; 43: 35-43.
50. Racz B, Horvath G, Reglodi D, et al. PACAP ameliorates oxidative stress in the chicken inner ear: an in vitro study. Regul Pept 2010; 160: 91-8.
51. Horvath G, Reglodi D, Opper B, et al. Effects of PACAP on the oxidative stress induced cell death in chicken pinealocytes is influenced by the phase of the circadian clock. Neurosci Lett 2010; 484: 148-52.
52. Stumm R, Kolodziej A, Prinz V, Endres M, Wu DF, Höllt V. Pituitary adenylate cyclase-activating polypeptide is up-regulated in cortical pyramidal cells after focal ischemia and protects neurons from mild hypoxic/ischemic damage. J Neurochem 2007; 103: 1666-81.
53. Onoue S, Ohshima K, Endo K, Yajima T, Kashimoto K. PACAP protects neuronal PC12 cells from the cytotoxicity of human prion protein fragment 106-126. FEBS Lett 2002; 522: 65-70.
54. Sanchez A, Rao HV, Grammas P. PACAP38 protects rat cortical neurons against the neurotoxicity evoked by sodium nitroprusside and thrombin. Regul Pept 2009; 152: 33-40.
55. Reglodi D, Tamas A, Lubics A, Szalontay L, Lengvari I. Morphological and functional effects of PACAP in a 6-hydroxydopamineinduced lesion of the substantia nigra in rats. Regul Pept 2004; 123: 85-94.
56. Reglodi D, Lubics A, Tamas A, Szalontay L, Lengvari I. Pituitary adenylate cyclase activating polypeptide protects dopaminergic neurons and improves behavioral deficits in a rat model of Parkinson's disease. Behav Brain Res 2004; 151: 303-12.
57. Reglodi D, Lubics A, Kiss P, et al. Effect of PACAP in 6-OHDAinduced injury of the substantia nigra in intact young and ovariectomized female rats. Neuropeptides 2006; 40: 265-74.
58. Reglodi D, Tamas A, Lengvari I, Toth G, Szalontay L, Lubics A. Comparative study on the effects of PACAP in young, aging, and castrated males in a rat model of Parkinson's disease. Ann NY Acad Sci 2006; 1070: 518-24.
59. Atlasz T, Szabadfi K, Kiss P, et al. PACAP-mediated neuroprotection of neurochemically identified cell types in MSG-induced retinal regeneration. J Mol Neurosci 2008; 36: 97-104.
60. Atlasz T, Szabadfi K, Reglodi D, et al. Effects of pituitary adenylate cyclase activating polypeptide (PACAP1-38) and its fragments on retinal degeneration induced by neonatal MSG treatment. Ann NY Acad Sci 2009; 1163: 348-52.
61. Babai N, Atlasz T, Tamás A, Reglodi D, Kiss P, Gábriel R. Degree of damage compensation by various PACAP treatments in monosodium glutamate-induced retina degeneration. Neurotox Res 2005; 8: 227-33.
62. Babai N, Atlasz T, Tamas A, et al. Search for the optimal monosodium glutamate treatment schedule to study the neuroprotective effects of PACAP in the retina. Ann NY Acad Sci 2006; 1070: 149-55.
63. Kiss P, Atlasz T, Szabadfi K, et al. Conparison between PACAPand enriched environment-induced retinal protection in MSGtreated newborn rats. Neurosci Lett 2011; 487:400-5.
64. Racz B, Gallyas F Jr., Kiss P, et al. The neuroprotective effects of PACAP in monosodium glutamate-induced retinal lesion involves inhibition of proapoptotic signaling pathways. Regul Pept 2006; 137: 20-6.
65. Racz B, Tamas A, Kiss P, et al. Involvement of ERK and CREB signalling pathways in the protective effect of PACAP on monosodium glutamate-induced retinal lesion. Ann NY Acad Sci 2006; 1070: 507-11.
66. Racz B, Gallyas F Jr, Kiss P, et al. Effects of pituitary adenylate cyclase activating polypeptide (PACAP) on the PKA-Bad-14-3-3 signaling pathway in glutamate-induced retinal injury in neonatal rats. Neurotox Res 2007; 12: 95-104.
67. Tamas A, Gabriel R, Racz B, et al. Effects of pituitary adenylate cyclase activating polypeptide in retinal degeneration induced by monosodium-glutamate. Neurosci Lett 2004; 372: 110-3.
68. Varga B, Szabadfi K, Kiss P, Fabian E, Tamas A, Griecs M, et al. PACAP improves functional outcome in excitotoxic retinal lesion: an electroretinographic study. J Mol Neurosci 2011, 43: 44-50.
69. Atlasz T, Szabadfi K, Kiss P, et al. Pituitary adenylate cyclase activating polypeptide in the retina: focus on the retinoprotective effects. Ann NY Acad Sci 2010; 1200: 128-39.
70. Rabl K, Reglodi D, Banvolgyi T, Somogyvari-Vigh A, Lengvari I, Gabriel R, et al. PACAP inhibits anoxia-induced changes in physiological responses in horizontal cells in the turtle retina. Regul Pept 2002; 109: 71-4.
71. Chen Y, Samal B, Hamelink CR, et al. Neuroprotection by endogenous and exogenous PACAP following stroke. Regul Pept 2006; 137: 4-19.
72. Dokrukol-Ak D, Kumar VB, Ryeerse JS, et al. Isolation of peptide transport system-6 from brain endothelial cells: therapeutic effects with antisense inhibition in Alzheimer and stroke models. J Cereb Blood Flow Metab 2009; 29: 411-22.
73. Ohtaki H, Nakamachi T, Dohi K, et al. Pituitary adenylate cyclaseactivating polypeptide (PACAP) decreases ischemic neuronal cell death in association with IL-6. Proc Natl Acad Sci USA 2006; 103: 7488-93.
74. Reglodi D, Somogyvari-Vigh A, Vigh S, Kozicz T, Arimura A. Delayed systemic administration of PACAP38 is neuroprotective in transient middle cerebral artery occlusion in the rat. Stroke 2000; 31: 1411-7.
75. Reglodi D, Somogyvari-Vigh A, Vigh S, Maderdrut JL, Arimura A. Neuroprotective effects of PACAP38 in a rat model of transient focal ischemia under various experimental conditions. Ann N Y Acad Sci 2000; 921: 119-28.
76. Reglodi D, Tamas A, Somogyvari-Vigh A, et al. Effects of pretreatment with PACAP on the infarct size and functional outcome in rat permanent focal cerebral ischemia. Peptides 2002; 23: 2227-34.
77. Tamas A, Reglodi D, Szanto Z, Borsiczky B, Nemeth J, Lengvari I. Comparative neuroprotective effects of preischemic PACAP and VIP administration in permanent occlusion of the middle cerebral artery in rats. Neuroendocrinol Lett 2002; 23: 249-54.
78. Dohi K, Mizushima H, Nakajo S, et al. Pituitary adenylate cyclaseactivating polypeptide (PACAP) prevents hippocampal neurons from apoptosis by inhibiting JNK/SAPK and p38 signal transduction pathways. Regul Pept 2002; 109: 83-8.
79. Shioda S, Ozawa H, Dohi K, et al. PACAP protects hippocampal neurons against apoptosis: involvement of JNK/SAPK signaling pathway. Ann NY Acad Sci 1998; 865: 111-7.
80. Uchida D, Arimura A, Somogyvari-Vigh A, Shioda S, Banks WA. Prevention of ischemia-induced death of hippocampal neurons by pituitary adenylate cyclase activating polypeptide. Brain Res 1996; 736: 280-6.
81. Atlasz T, Babai N, Kiss P, et al. Pituitary adenylate cyclase activating polypeptide is protective in bilateral carotid occlusion-induced retinal lesion in rats. Gen Comp Endocrinol 2007; 153: 108-14.
82. Atlasz T, Szabadfi K, Kiss P, et al. Evaluation of the protective effects of PACAP with cell-specific markers in ischemia-induced retinal degeneration. Brain Res Bull 2010; 81: 497-504.
83. Seki T, Itoh H, Nakamachi T, et al. Suppression of rat retinal ganglion cell death by PACAP following transient ischemia induced by high intraocular pressure. J Mol Neurosci 2011; 43: 30-4.
84. Atlasz T, Koszegi Zs, Babai N, et al. Microiontophoretically applied PACAP blocks excitatory effects of kainic acid in vivo. Ann NY Acad Sci 2006; 1070: 143-8.
85. Seki T, Nakatani M, Taki C, et al. Neuroprotective effect of PACAP against kainic acid-induced neurotoxicity in rat retina. Ann NY Acad Sci 2006; 1070: 531-4.
86. Guillot TS, Richardson JR, Wang MZ, et al. PACAP38 increases vesicular monoamine transporter 2 (VMAT2) expression and attenuates methamphetamine toxicity. Neuropeptides 2008; 42: 423-34.
87. Deguil J, Chavant F, Lafay-Chebassier C, Pérault-Pochat MC, Fauconneau B, Pain S. Neuroprotective effect of PACAP on translational control alteration and cognitive decline in MPTP parkinsonian mice. Neurotox Res 2010;17:142-55.
88. Wang G, Pan J, Tan YY, et al. Neuroprotective effects of PACAP27 in mice model of Parkinson's disease involved in the modulation of K(ATP) subunits and D2 receptors in the striatum. Neuropeptides 2008; 42: 267-76.
89. Seki T, Itoh H, Nakamachi T, Shioda S. Suppression of ganglion cell death by PACAP following optic nerve transection in the rat. J Mol Neurosci 2008; 36: 57-60.
90. Takei N, Torres E, Yuhara A, et al. Pituitary adenylate cyclase activating polypeptide promotes the survival of basal forebrain cholinergic neurons in vitro and in vivo: comparison with effects of nerve growth factor. Eur J Neurosci 2000; 12: 2273-80.
91. Kimura H, Kawatani M, Ito E, Ishikawa K. PACAP facilitates the nerve regeration factors in the facial nerve injury. Regul Pept 2004; 123: 135-8.
92. Endo K, Nakamachi T, Seki T, et al. Neuroprotective Effect of PACAP Against NMDA-Induced Retinal Damage in the Mouse. J Mol Neurosci 2011; 43: 22-9.
93. Tamas A, Lubics A, Lengvari I, Reglodi D. Protective effects of PACAP in excitotoxic striatal lesion. Ann NY Acad Sci 2006; 1070: 570-4.
94. Kovesdi E, Tamas A, Reglodi D, et al. Posttraumatic administration of pituitary adenylate cyclase activating polypeptide in central fluid percussion injury in rats. Neurotox Res 2008; 13: 71-8.
95. Farkas O, Tamas A, Zsombok A, et al. Effects of pituitary adenylate cyclase activating polypeptide (PACAP) in a rat model of traumatic brain injury. Regul Pept 2004; 123: 69-75.
96. Tamas A, Zsombok A, Farkas O, et al. Postinjury administration of pituitary adenylate cyclase activating polypeptide (PACAP) attenuates traumatically induced axonal injury in rats. J Neurotrauma 2006; 23: 686-95.
97. Chen WH, Tzeng SF. Pituitary adenylate cyclase-activating polypeptide prevents cell death in the spinal cord with traumatic injury. Neurosci Lett 2005; 384: 117-21.
98. Fang KM, Chen JK, Hung SC, et al. Effects of combinatorial treatment with pituitary adenylate cyclase activating Peptide and human mesenchymal stem cells on spinal cord tissue repair. PLoS One 2010; 5: e15299.
99. Atlasz T, Szabadfi K, Kiss P, et al. Effects of PACAP in UV-A rediation-induced retinal degeneration models in rats. J Mol Neurosci 2011; 43: 51-7.
100. Joo KM, Chung YH, Kim MK, et al. Distribution of vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide receptors (VPAC1, VPAC2, and PAC1 receptor) in the rat brain. J Comp Neurol 2004; 476: 388-413.
101. Palkovits M, Somogyvári-Vigh A, Arimura A. Concentrations of pituitary adenylate cyclase activating polypeptide (PACAP) in human brain nuclei. Brain Res 1995; 699: 116-20.
102. Hashimoto H, Nogi H, Mori K, et al. Distribution of the mRNA for a pituitary adenylate cyclase-activating polypeptide receptor in the rat brain: an in situ hybridization study. J Comp Neurol 1996; 371: 567-77.
103. Shioda S, Shuto Y, Somogyvari-Vigh A, et al. Localization and gene expression of the receptor for pituitary adenylate cyclaseactivating polypeptide in the rat brain. Neurosci Res 1997; 28:345-54.
104. Kalló I, Kalamatianos T, Piggins HD, Coen CW. Ageing and the diurnal expression of mRNAs for vasoactive intestinal peptide and for the VPAC2 and PAC1 receptors in the suprachiasmatic nucleus of male rats. J Neuroendocrinol 2004; 16: 758-66.
105. Joo KM, Chung YH, Lim HC, Lee KH, Cha CI. Reduced immunoreactivities of a vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide receptor (VPAC1 receptor) in the cerebral cortex, hippocampal region, and amygdala of aged rats. Brain Res 2005; 1064: 166-72.
106. Lee JC, Cho YJ, Kim J, et al. Region-specific changes in the immunoreactivity of vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide receptors (VPAC2, and PAC1 receptor) in the aged rat brains. Brain Res 2010; 1351: 32-40.
107. Krajnak K, Lillis TO. Aging alters light-and PACAP-induced cAMP accumulation in the suprachiasmatic nucleus of female rats. Brain Res 2002; 950: 297-303.
108. Ohtaki H, Satoh A, Nakamachi T, et al. Regulation of oxidative stess by pituitary adenylate cyclase activating polypeptide (PACAP) mediated by PACAP receptor. J Mol Neurosci 2010; 42: 397-403.
109. Masuo Y, Ohtaki T, Masuda Y, Tsuda M, Fujino M. Binding sites for pituitary adenylate cyclase activating polypeptide (PACAP): comparison with vasoactive intestinal polypeptide (VIP) binding site localization in rat brain sections. Brain Res. 1992; 575: 113-23.
110. Arbogast LA, Voogt JL. Pituitary adenylate cyclase activating polypeptide (PACAP) increases prolactin release and tuberoinfundibular dopaminergic neuronal activity. Brain Res 1994; 655: 17-24.
111. Bringmann G, Feineis D, God R, et al. 1-Trichloromethyl-1,2,3,4-tetrahydro-beta-carboline (TaClo) and related derivatives: chemistry and biochemical effects on catecholamine biosynthesis. Bioorg Med Chem 2002;10: 2207-14.
112. Houchi H, Hamano S, Masuda Y, et al. Stimulatory effect of pituitary adenylate cyclase-activating polypeptide on catecholamine synthesis in cultured bovine adrenal chromaffin cells: involvements of tyrosine hydroxylase phosphorylation caused by Ca2+ influx and cAMP. Jpn J Pharmacol 1994; 66: 323-30.
113. Houchi H, Azuma M, Kitamura K, Okuno M, Oka M. Pituitary adenylate cyclase-activating polypeptide stimulates the synthesis of dopamine in cultured bovine adrenal chromaffin cells. Hypertens Res 1995; 18 Suppl 1: S169-71.
114. Moser A, Scholz J, Gansle A. Pituitary adenylate cyclase activating polypeptide (PACAP-27) enhances tyrosine hydroxylase activity in the nucleus accumbens of the rat. Neuropeptides 1999; 33: 492-7.
115. Nanmoku T, Isobe K, Sakurai T, et al. Orexins suppress catecholamine synthesis and secretion in cultured PC12 cells. Biochem Bipphys Res Commun 2000; 274: 310-15.
116. Bobrovskaya L, Gelain DP, Gilligan C, Dickson PW, Dunkley PR. PACAP stimulates the sustained phosphorylation of tyrosine hydroxylase at serine 40. Cell Signal 2007; 19: 1141-9.
117. Corbitt J, Vivekananda J, Wang SS, Strong R. Transcriptional and posttranscriptional control of tyrosine hydroxylase gene expression during persistent stimulation of pituitary adenylate cyclaseactivating polypeptide receptors on PC12 cells: regulation by protein kinase A-dependent and protein kinase A-independent pathways. J Neurochem 1998; 71: 478-86.
118. Corbitt J, Hagerty T, Fernandez E, Morgan WW, Strong R. Transcriptional and post-transcriptional regulation of tyrosine hydroxylase messenger RNA in PC12 cells during persistent stimulation by VIP and PACAP38: differential regulation by protein kinase A and protein kinase C-dependent pathways. Neuropeptides 2002; 36: 34-45.
119. Rius RA, Guidotti A, Costa E. Pituitary adenylate cyclase activating polypeptide (PACAP) potently enhances tyrosine hydroxylase (TH) expression in adrenal chromaffin cells. Life Sci 1994; 54: 1735-43.
120. Mokrey J. Experimental models and behavioral tests used in the study of Parkinson's disease. Physiol Res 1995; 44: 143-50.
121. Prediger RD, Aguiar AS Jr, Rojas-Mayorquin AE, et al. Single intranasal administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in C57BL/6 mice models early preclinical phase of Parkinson's disease. Neurotox Res 2010; 17: 114-29.
122. Delgado M, Ganea D. Neuroprotective effect of vasoactive intestinal peptide (VIP) in a mouse model of Parkinson's disease by blocking microglial activation. FASEB J 2003; 17: 944-6.
123. Schwarting RW, Huston JP. The unilateral 6-hydroxydopamine lesion model in behavioral brain research: analysis of functional deficits, recovery and treatments. Prog Neurobiol 1996; 50: 275-331.
124. Schwarting RW, Huston JP. Unilateral 6-hydroxydopamine lesions of meso-striatal dopamine neurons and their physiological sequelae. Prog Neurobiol 1996; 49: 215-66.
125. Tamas A, Lubics A, Szalontay L, Lengvari I, Reglodi D. Age-and gender differences in behavioral and morphological outcome after 6-hydroxydopamine-induced lesion of the substantia nigra in rats. Behav Brain Res 2005; 158: 221-9.
126. Tamas A, Lubics A, Lengvari I, Reglodi D. Effects of age, gender, and gonadectomy on neurochemistry and behavior in animal models of Parkinson's disease. Endocrine 2006; 29: 275-87.
127. Pirger Z, Laszlo Z, Kemenes I, Toth G, Reglodi D, Kemenes G. A homolog of the vertebrate pituitary adenylate cyclase-activating polypeptide is both necessary and instructive for the rapid formation of associative memory in an invertebrate. J Neurosci. 2010; 30: 13766-73.
128. Otto C, Kovalchuk Y, Wolfer DP, et al. Impairment of mossy fiber long-term potentiation and associative learning in pituitary adenylate cyclase activating polypeptide type I receptor-deficient mice. J Neurosci 2001; 21: 5520-7.
129. Telegdy G, Kokavszky K. The action of pituitary adenylate cyclase activating polypeptide (PACAP) on passive avoidance learning. The role of neurotransmitters. Brain Res 2000; 874: 194-9.
130. Sacchetti B, Lorenzini CA, Baldi E, et al. Pituitary adenylate cyclase-activating polypeptide hormone (PACAP) at very low dosages improves memory in the rat. Neurobiol Learn Mem 2001; 76: 1-6.
131. Roberto M, Brunelli M. PACAP-38 enhances excitatory synaptic transmission in the rat hippocampal CA1 region. Learn Mem 2000; 7: 303-11.
132. Hagino N. Performance of PAC1-R heterozygous mice in memory tasks-II. J Mol Neurosci 2008; 36: 208-19.
133. Hashimoto H, Shintani N, Baba A. Higher brain functions of PACAP and a homologous Drosophila memory gene amnesiac: insights from knockouts and mutants. Biochem Biophys Res Commun 2002; 297: 427-31.
134. Sauvage M, Brabet P, Holsboer F, Bockaert J, Steckler T. Mild deficits in mice lacking pituitary adenylate cyclase-activating polypeptide receptor type 1 (PAC1) performing on memory tasks. Brain Res Mol Brain Res 2000; 84: 79-89.
135. Matsuyama S, Matsumoto A, Hashimoto H, Shintani N, Baba A. Impaired long-term potentiation in vivo in the dentate gyrus of pituitary adenylate cyclase-activating polypeptide (PACAP) or PACAP type 1 receptor-mutant mice. Neuroreport 2003; 14: 2095-8.
136. Wu ZL, Ciallella JR, Flood DG, O'Kane TM, Bozyczko-Coyne D, Savage MJ. Comparative analysis of cortical gene expression in mouse models of Alzheimer's disease. Neurobiol Aging 2006; 27: 377-86.
137. Vaudry D, Cottet-Rousselle C, Basille M, et al. Pituitary adenylate cyclase-activating polypeptide inhibits caspase-3 activity but does not protect cerebellar granule neurons against beta-amyloid (25-35)-induced apoptosis. Regul Pept 2004; 123: 43-9.
138. Fahrenholz F. Alpha-secretase as a therapeutic target. Curr Alzheimer Res. 2007; 4: 412-7.
139. Kojro E, Postina R, Buro C, Meiringer C, Gehrig-Burger K, Fahrenholz F. The neuropeptide PACAP promotes the alpha-secretase pathway for processing the Alzheimer amyloid precursor protein. FASEB J. 2006; 20: 512-4.
140. Banks WA, Kastin AJ, Komaki G, Arimura A. Passage of pituitary adenylate cyclase activating polypeptide1-27 and pituitary adenylate cyclase activating polypeptide1-38 across the blood-brain barrier. J Pharmacol Exp Ther 1993; 267: 690-6.
141. Dogrukol-Ak D, Tore F, Tuncel N. Passage of VIP/PACAP/secretin family across the blood-brain barrier: therapeutic effects. Curr Pharm Des 2004; 10: 1325-40.
142. Nonaka N, Banks WA, Mizushima H, Shioda S, Morley JE. Regional differences in PACAP transport across the blood-brain varrier in mice: a possible influence of strain, amyloid beta protein, and age. Peptides 2002; 23: 2197-202.
143. Gonzalez-Rey E, Varela N, Chorny A, Delgado M. Therapeutical approaches of vasoactive intestinal peptide as a pleiotropic immunomodulator. Curr Pharm Des 2007; 13: 1113-39.
144. Delgado M, Jonakait GM, Ganea D. Vasoactive intestinal peptide and pituitary adenylate cyclase activating polypeptide inhibit chemokine production in activated microglia. Glia 2002; 39: 148-61.
145. Delgado M, Leceta J, Ganea D. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit the production of inflammatory mediators by activated microglia. J Leukoc Biol 2003; 73: 155-64.
146. Suk K, Park JH, Lee WH. Neuropeptide PACAP inhibits hypoxic activation of brain microglia: a protective mechanism against microglial neurotoxicity in ischemia. Brain Res 2004; 1026: 151-6.
147. Nakamachi T, Li M, Shioda S, Arimura A. Signaling involved in pituitary adenylate cyclase-activating polypeptide-stimulated ADNP expression. Peptides 2006; 27: 1859-64.
148. Nakamachi T, Ohtaki H, Yofu S, et al. Pituitary adenylate cyclaseactivating polypeptide (PACAP) type 1 receptor (PAC1R) colocalizes with activity-dependent neuroprotective protein (ADNP) in the mouse brains. Regul Pept 2008; 145: 88-95.
149. Zusev M, Gozes I. Differential regulation of activity-dependent neuroprotective protein in rat asctrocytes by VIP and PACAP. Regul Pept 2004; 123: 33-41.
150. Gozes I. Davunetide (NAP) pharmacology: Neuroprotection and tau. In: Emerging Drugs and Targets for Alzheimer's Disease, 1st Edition (Martinez A, ed), pp 108-128. Cambridge: Royal Society of Chemistry. 2010.
151. Fernandez-Montesinos R, Torres M, Baglietto-Vargas D, et al. Activity-dependent neuroprotective protein (ADNP) expression in the amyloid precursor protein/presenilin 1 mouse model of Alzheimer's disease. J Mol Neurosci 2010; 41:114-20.
152. Gozes I, Morimoto BH, Tiong J, et al. NAP: research and development of a peptide derived from activity-dependent neuroprotective protein (ADNP). CNS Drug Rev 2005; 11: 353-68.
153. Koshimizu H, Senatorov V, Loh YP, Gozes I. Neuroprotective protein and carboxypeptidase E. J Mol Neurosci 2009; 39: 1-8.
154. Offen D, Sherki Y, Melamed E, Fridkin M, Brenneman DE, Gozes I. Vasoactive intestinal peptide (VIP) prevents neurotoxicity in neuronal cultures: relevance to neuroprotection in Parkinson's disease. Brain Res 2000; 854: 257-62.
155. Zemlyak I, Furman S, Brenneman DE, Gozes I. A novel peptide prevents death in enriched neuronal cultures. Regul Pept 2000; 96: 39-43.
156. Bassan M, Zamostiano R, Davidson A, et al. Complete sequence of a novel protein containing a femtomolar-activity-dependent neuroprotective peptide. J Neurochem 1999; 72: 1283-93.
157. Gozes I, Giladi E, Pinhasov A, Bardea A, Brenneman DE. Activity-dependent neurotrophic factor: intranasal administration of femtomolar-acting peptides improve performance in a water maze. J Pharmacol Exp Ther 2000; 293: 1091-8.
158. Matsuoka Y, Gray A, Hirata-Fukae C, et al. Intranasal NAP administration reduces accumulation of amyloid peptide and tau hyperphosphorylation in a transgenic mouse model of Alzheimer's disease at early pathological stage. J Mol Neurosci 2007; 31: 165-70.
159. Matsuoka Y, Jouroukhin Y, Gray AJ, et al. A neuronal microtubule-interacting agent, NAPVSIPQ, reduces tau pathology and enhances cognitive function in a mouse model of Alzheimer's disease. J Pharmacol Exp Ther 2008; 325: 146-53.
160. Shiryaev N, Jouroukhin Y, Giladi E, et al. NAP protects memory, increases soluble tau and reduces tau hyperphosphorylation in a tauopathy model. Neurobiol Dis 2009; 34: 381-8.
161. Fleming SM, Mulligan CK, Richter F, et al. A pilot trial of the microtubule-interacting peptide (NAP) in mice overexpressing alpha-synuclein shows improvement in motor function and reduction of alpha-synuclein inclusions. Mol Cell Neurosci. 2011; 46: 597-606.
162. Masmoudi-Kouki O, Gandolfo P, Castel H, et al. Role of PACAP and VIP in astroglial functions. Peptides 2007; 28: 1753-60.
163. Masuo Y, Noguchi J, Morita S, Matsumoto Y. Effects of intracerebroventricular administration of pituitary adenylate cyclaseactivating polypeptide (PACAP) on the motor activity and reserpine-induced hypothermia in murines. Brain Res 1995; 700: 219-26.
164. Morley JE, Horowitz M, Morley PM, Flood JF. Pituitary adenylate cyclase activating polypeptide (PACAP) reduces food intake in mice. Peptides 1992; 13: 1133-5.
165. Reglodi D, Kiss P, Tamás A, Lengvári I. The effects of PACAP and PACAP antagonist on the neurobehavioral development of newborn rats. Behav Brain Res 2003; 140: 131-9.
166. Yang K, Lei G, Jackson MF, Macdonald JF. The involvement of PACAP/VIP system in the synaptic transmission in the hippocampus. J Mol Neurosci 2010; 42: 319-26.
167. Reichenstein M, Rehavi M, Pinhasov A. Involvement of pituitary adenylate cyclase activating polypeptide (PACAP) and its receptors in the mechanism of antidepressant action. J Mol Neurosci 2008; 36: 330-8.
168. Birk S, Sitarz JT, Petersen KA, et al. The effect of intravenous PACAP38 on cerebral hemodynamics in healthy volunteers. Regul Pept 2007; 140:185-91.
169. Seeliger S, Buddenkotte J, Schmidt-Choudhury A, et al. Pituitary adenylate cyclase activating polypeptide: an important vascular regulator in human skin in vivo. Am J Pathol 2010; 177: 2563-75.
170. Schytz HW, Birk S, Wienecke T, Kruuse C, Olesen J, Ashina M. PACAP38 induces migraine-like attacks in patients with migraine without aura. Brain 2009; 132: 16-25.
171. Krishnadas A, Onyuksel H, Rubinstein I. Interactions of VIP, secretin and PACAP1-38 with phospholipids: a biological paradix revisited. Curr Pharm Des 2003; 9: 1005-12.
172. Komi N, Okawa K, Tateishi Y, Shirakawa M, Fujiwara T, Akutsu H. Structural analysis of pituitary adenylate cyclase activating polypeptides bound to phospholipids by magic angle spinning solid-state NMR. Biochim Biophys Acta 2007; 1768: 3001-11.
173. Bourgault S, Vaudry D, Botia B, et al. Novel stable PACAP analogs with potent activity towards the PAC1 receptor. Peptides 2008; 29: 919-32.
174. Bourgault S, Vaudry D, Ségalas-Milazzo I, et al. Molecular and conformational determinants of pituitary adenylate cyclaseactivating polypeptide (PACAP) for activation of the PAC1 receptor. J Med Chem 2009; 52: 3308-16.
175. Chapter MC, White CM, DeRidder A, Chadwick W, Martin B, Maudsley S. Chemical modification of class II G protein-coupled receptor ligands: frontiers in the development of peptide analogs as neuroendocrine pharmacological therapies. Pharmacol Ther 2010; 125: 39-54.
176. Chu A, Caldwell JS, Chen YA. Identification and characterization of a small molecule antagonist of human VPAC(2) receptor. Mol Pharmacol 2010; 77: 95-101.
177. Doan ND, Bourgault S, Dejda A, et al. Design and in vitro characterization of PAC1/VPAC1-selective agonists with potent neuroprotective effects. Biochem Pharmacol 2011; 81: 552-61.
178. Onoue S, Hanato J, Kuriyama K, Mizumoto T, Yamada S. Development of PACAP38 Analogue with Improved Stability: Physicochemical and in vitro/in vivo pharmacological characterization. J Mol Neurosci 2011; 43: 85-93.
179. Wang W, Martin-Moe S, Pan C, Musza L, Wang YJ. Stabilization of a polypeptide in non-aqueous solvents. Int J Pharm 2008; 351: 1-7.
180. Yu R, Li J, Wang J, Liu X, Huang L, Ding Y, Chen J. The functional recombinant first extracellular (EC1) domain of PACAP receptor PAC1 normal form (PAC1-EC1(N) recognizes selective ligands and stimulates the proliferation of PAC1-CHO cells. Neurosci Lett 2010; 480: 73-7.
181. Gozes I, Perl O, Giladi E, et al. Mapping the active site in vasocative intestinal peptide to a core of four amino acids: neuroprotective drug design. Proc Natl Acad Sci ISA 1999; 96: 4143-8.